Local Institution

Jaú, São Paulo 17210-120

0 studies enrolling now · 9 studies all time

What they study most

Breast Cancer, Cancer of the Stomach, Endometrial Cancer, Gastric Cancer, Gastroesophageal Junction, Hepato Cellular Carcinoma (HCC), Melanoma, Metastases, Myeloid Leukemia, Chronic, Prostatic Neoplasms, Stage III (Unresectable) or Stage IV Advanced Melanoma, Stomach Cancer

Studies at this site

• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma — Withdrawn before enrolling
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• Expanded Access Program With Nivolumab to Treat Melanoma — NO_LONGER_AVAILABLE
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies — Completed
• Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma — Completed